FDA CVM Update · Drug Approval · March 14, 2025
FDA Conditionally Approves Drug for Management of Ventricular Hypertrophy in Cats
FDA conditionally approved Felycin-CA1 (sirolimus delayed-release tablets) for management of ventricular hypertrophy in cats with subclinical hypertrophic cardiomyopathy, the first approved product for cats with HCM for any indication.